# US 2025/0084186 A1 · Anti-cd28 x anti-enpp3 antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0084186 A1
- Document ID: US20250084186A1
- Status: Published application
- Kind: A1
- Application number: 18/634,868
- Filed: 2024-04-12
- Published: 2025-03-13
- Earliest claimed: 2023-04-14
- Assignees: Xencor, Inc.
- Applicants: Xencor, Inc.
- Inventors: Alex Nisthal; Suzanne Schubbert; Gregory Moore; Rumana Rashid; Patrick Arpp; Ernesto Delgado; ChaoFang Tan
- Web page: https://patentgrep.com/patent/US20250084186A1

## CPC

- C07K 16/40: against enzymes
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/30: from tumour cells
- C12Y 306/01009: Nucleotide diphosphatase (3.6.1.9), i.e. nucleotide-pyrophosphatase
- A61P 35/00: Antineoplastic agents
- C07K 2317/31: multispecific
- C07K 2317/51: Complete heavy chain or Fd fragment, i.e. VH + CH1
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/54: F(ab')2
- C07K 2317/55: Fab or Fab'
- C07K 2317/60: characterized by non-natural combinations of immunoglobulin fragments
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are novel anti-CD28×anti-ENPP3 antibodies and methods of using such antibodies for the treatment of ENPP3-associated cancers. Subject anti-CD28×anti-ENPP3 antibodies are capable of agonistically binding to CD28 costimulatory molecules on T cells and ENPP3 on tumor cells. Thus, such antibodies selectively enhance anti-tumor activity at tumor sites while minimizing peripheral toxicity. The subject antibodies provided herein are particularly useful in combination with other anti-cancer therapies, including, for example, bispecific antibodies for the treatment of ENPP3-associated cancers.

## Claims

### Claim at position 1

-82. (canceled)

### Claim 83

A bispecific antibody comprises a means for binding carcinoembryonic antigen-related cell adhesion molecule 5 (ENPP3) and a means for binding CD28.

### Claim 84

A bispecific antibody comprising:
a) a carcinoembryonic antigen-related cell adhesion molecule 5 (ENPP3) binding domain comprising i) a first variable heavy domain (VH1), and ii) a first variable light domain (VL1); and
b) an anti-CD28 binding domain comprising i) a second variable heavy domain (VH2), and ii) a second variable light domain (VL2).

### Claim 85 (depends on 84)

The bispecific antibody of claim 84, wherein VH1 and VL1 a VH and VL of any of the ENPP3 binding domains from FIG. 22.

### Claim 86 (depends on 84)

The bispecific antibody according to claim 84, wherein VH2 and VL2 are selected from one of the following:
(1) a VH and VL of any of the CD28 binding domains from FIGS. 15, 18, and 21; or
(2) (i) a VH from FIGS. 15 or 16, or a variant thereof, and (ii) a VL from FIGS. 15 or 17.

### Claim 87

A heterodimeric antibody comprising:
a) a first monomer comprising:
i) a single chain variable fragment (scFv); and
ii) a first Fc domain, wherein the scFv is covalently attached to the N-terminus of the first Fc domain using a domain linker;
b) a second monomer comprising, from N-terminal to C-terminal, a VH1-CH1-hinge-CH2-CH3, wherein VH1 is a first variable heavy domain and CH2-CH3 is a second Fc domain; and
c) a light chain comprising, from N-terminal to C-terminal, VL1-CL, wherein VL1 is a first variable light domain and CL is a constant light domain,
wherein the scFv comprises a second VH domain (VH2), a scFv linker, and a second variable light domain (VL2),
wherein the VH1 and the VL1 together form a first antigen binding domain (ABD) and the VH2 and the VL2 together form a second ABD, and
wherein one of the first ABD and second ABD is a CD28 binding domain and the other of the first ABD and second ABD is a Ectonucleotide Pyrophosphatase/Phosphodiesterase 3 (ENPP3) binding domain.

### Claim 88 (depends on 87)

The heterodimeric antibody according to claim 87, wherein VH1 and VL1 are a VH and VL of any of the ENPP3 binding domains from FIG. 22 or a variant thereof.

### Claim 89 (depends on 87)

The heterodimeric antibody according to claim 87, wherein VH2 and VL2 are selected from one of the following:
(1) a VH and VL of any of the CD28 binding domains from FIGS. 15, 18, and 21 or a variant thereof, or
(2) (i) a VH from FIGS. 15 or 16, or a variant thereof, and (ii) a VL from FIGS. 15 or 17, or a variant thereof.

### Claim 90 (depends on 87)

A nucleic acid composition comprising:
a) a first nucleic acid encoding the first monomer of claim 87;
b) a second nucleic acid encoding the second monomer of claim 87; and
c) a third nucleic acid encoding the light chain of claim 87.

### Claim 91 (depends on 90)

An expression vector composition comprising:
a) a first expression vector comprising the first nucleic acid of claim 90;
b) a second expression vector comprising the second nucleic acid of claim 90; and
c) a third expression vector comprising the third nucleic acid of claim 90.

### Claim 92 (depends on 91)

A host cell comprising the expression vector composition of claim 91.

### Claim 93 (depends on 92)

A method of making a heterodimeric antibody comprising culturing the host cell of claim 92 under conditions wherein the heterodimeric antibody is expressed and recovering the heterodimeric antibody.

### Claim 94

A heterodimeric antibody comprising:
a) a first monomer comprising an amino acid sequence of SEQ ID NO:745;
b) a second monomer comprising an amino acid sequence of SEQ ID NO:746; and
c) a light chain comprising an amino acid sequence of SEQ ID NO:747.

### Claim 95 (depends on 94)

A nucleic acid composition comprising:
a) a first nucleic acid encoding the first monomer of claim 94;
b) a second nucleic acid encoding the second monomer of claim 94; and
c) a third nucleic acid encoding the light chain of claim 94.

### Claim 96 (depends on 95)

An expression vector composition comprising:
a) a first expression vector comprising the first nucleic acid of claim 95;
b) a second expression vector comprising the second nucleic acid of claim 95; and
c) a third expression vector comprising the third nucleic acid of claim 95.

### Claim 97 (depends on 96)

A host cell comprising the expression vector composition of claim 96.

### Claim 98 (depends on 97)

A method of making a heterodimeric antibody comprising culturing the host cell of claim 97 under conditions wherein the heterodimeric antibody is expressed and recovering the heterodimeric antibody.
